Fetal And Neonatal Therapy To Improve Perinatal Outcome And Long-term Neurodevelopment
Funder
National Health and Medical Research Council
Funding Amount
$214,032.00
Summary
I am a consultant neonatologist with a half-time research appointment. Preventing perinatal morbidity and mortality is one of the greatest challenges in medicine today. My vision is to lead research into new fetal and neonatal therapies, foster collaborations with clinicians and scientists, and improve clinical practice. The scope of my research includes “brain-oriented” program of neonatal intensive care, neuroprotective strategies, and devising new fetal together with the obstetricians.
Unlocking The Complexities Of Postnatal Brain Injury In Preterm Neonates.
Funder
National Health and Medical Research Council
Funding Amount
$408,388.00
Summary
Brain injury is common in preterm infants and is responsible for significant death or life long disease such as cerebral palsy. Brain injury can occur through many mechanisms however the immediate newborn period is identified as a most vulnerable period. This unique proposal utilises existing expertise and new technologies to advance our understanding of the physiological mechanisms behind the progression of brain injury in preterm neonates.
Control Of Cardiac And Skeletal Contractility By Luminal Calcium Store Load In Health And Disease
Funder
National Health and Medical Research Council
Funding Amount
$415,138.00
Summary
Disorders affecting skeletal muscle and the heart can have life threatening effects and lead to impaired mobility and sudden cardiac death. This project will uncover the mechanisms of disorders which lead to skeletal muscle fatigue, chemotherapy induced toxicity in the heart and heart failure. Understanding these mechanisms may lead to successful gene therapy treatment and to the design of a new range of drug therapies to treat these devastating disorders.
This application proposes to study in detail the main target cell for HIV infection, namely CCR5+ CD4 T lymphocytes. After 30 years of the pandemic, fundamental knowledge of these cells, such as locations in the body, differentiation from other lymphocytes, and survival, is still lacking. These attributes determine whether or not they will be infected by HIV, whether this can be prevented by vaccines or CCR5 blocking drugs, and whether their long-term survival results in an inability to eradicat ....This application proposes to study in detail the main target cell for HIV infection, namely CCR5+ CD4 T lymphocytes. After 30 years of the pandemic, fundamental knowledge of these cells, such as locations in the body, differentiation from other lymphocytes, and survival, is still lacking. These attributes determine whether or not they will be infected by HIV, whether this can be prevented by vaccines or CCR5 blocking drugs, and whether their long-term survival results in an inability to eradicate HIV.Read moreRead less
Using Gene Delivery Tools To Understand And Treat Skeletal Muscle-related Disease
Funder
National Health and Medical Research Council
Funding Amount
$459,270.00
Summary
As a muscle biologist, I study the mechanisms that regulate skeletal muscle size, so that we can develop therapies for muscle wasting. What sets my research apart is my combination of expertise in muscle biology, and the use of recombinant viral vectors for altering the expression of specific genes exclusively in skeletal muscles. Our approaches enable us to study the inner workings of muscles in ways others cannot, and develop promising new therapies for treating muscle diseases.
Advancing The Diagnosis And Treatment Of Inherited Muscle Disorders
Funder
National Health and Medical Research Council
Funding Amount
$408,388.00
Summary
Inherited myopathies collectively affect ~1 in 1000 people, cause life-long disability and often shortened life. This fellowship addresses two key areas of need. 1. New gene discovery for the inherited myopathies using the latest genetic techniques and 2. developing therapies. I will test two recently developed drugs as potential treatments for tropomyosin myopathies and investigate key areas of disease mechanism for tropomyosin and RYR1 myopathies to identify new therapeutic targets.